Millie
your market intelligence analyst
Search Results
22 results
Your search is now limited to «Chemotherapy» expert search.
ClinicalTrials.gov 11/15/2019 07:03
Conditions : Bladder Mixed Adenocarcinoma; Bladder Urothelial Carcinoma In Situ; High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage 0is Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8 Interventions : Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Biological: Pembrolizumab Sponsor : National Cancer Institute (NCI) Not yet recruiting.
ClinicalTrials.gov 11/15/2019 07:02
Condition : Carcinoma, Non-Small-Cell Lung Interventions : Biological: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Biological: MK-7684 Sponsor : Merck Sharp & Dohme Corp. Not yet recruiting.
Purpose:. High levels of tumor-infiltrating lymphocytes (TIL) before neoadjuvant chemotherapy (NAC) are associated with higher pathologic complete response (pCR) rates and better survival in triple-negative breast cancer (TNBC) and HER2 -positive breast cancer.

Automotive Industries

Business Issues

Companies - Public

Companies - Venture Funded

Global Markets

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Market Research Topics

Political Entities

Sources

Strategic Scenarios

Trends